Evaluation of hematological, virologic and anthropometric parameters as progression markers in HIV-1 infected children;Avaliação dos parâmetros hematológicos, virológicos e antropométricos como marcadores de progressão em crianças infectadas pelo HIV-1

Jornal de Pediatria

Volumn 85, Issue 2, 2009, Pages 149-156

  Carvalho, Inácio R ^a,b   Pinto, Jorge Andrade ^a,c   Cardoso, Claudete A A ^a   Candiani, Talitah M S ^a   Kakehasi, Fabiana M ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b FUNDAÇÃO HOSPITALAR DO ESTADO DE MINAS GERAIS   (Brazil)

^c UFMG ^*  (Brazil)

Author keywords

Biomarkers; Children; HIV; Lymphocytes; Weight age

Indexed keywords

ANTIRETROVIRUS AGENT; HEMOGLOBIN;

ANTHROPOMETRY; ARTICLE; BODY WEIGHT; CD4+ T LYMPHOCYTE; CELL COUNT; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL FEATURE; COHORT ANALYSIS; DEATH; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; FEMALE; FOLLOW UP; GROUPS BY AGE; HEMOGLOBIN BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL ADMISSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFANT; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NUTRITIONAL STATUS; POPULATION; PREDICTOR VARIABLE; RETROSPECTIVE STUDY; RISK ASSESSMENT; VIRUS LOAD; WORLD HEALTH ORGANIZATION;

EID: 65949117239     PISSN: 00217557     EISSN: None     Source Type: Journal    
DOI: 10.2223/JPED.1880     Document Type: Article

References (26)

1. Romanelli RM, Pinto J, Melo LJ, Vasconcelos MA, Pereira RM. Effectiveness of dual and triple antiretroviral therapy in the treatment of HIV-infected children. J Pediatr (Rio J). 2006;82:260-265
2. Candiani TM, Pinto J, Cardoso CA, Carvalho IR, Dias AC, Carneiro M, et al. Impact of highly active antiretroviral therapy (HAART) on the incidence of opportunistic infections, hospitalizations and mortality among children and adolescents living with HIV/AIDS in Belo Horizonte, Minas Gerais State, Brazil. Cad Saude Publica. 2007;23 Supl 3:S414-23.
3. Gona P, Van Dyke RB, Williams PL, Dankner WN, Chernoff MC, Nachman SA, et al. Incidence of opportunistic and other infections in HIV-infected children in the HAART era. JAMA. 2006;296:292-300. (Pubitemid 44079313)
4. Shearer WT, Quinn TC, LaRussa P, Lew JF, Mofenson L, Almy S, et al. Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group. N Engl J Med. 1997;336:1337-1342
5. Mofenson LM, Korelitz J, Meyer WA 3rd, Bethel J, Rich K, Pahwa S, et al. The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. J Infect Dis. 1997;175:1029-1038
6. Palumbo PE, Raskino C, Fiscus S, Pahwa S, Fowler MG, Spector AS, et al. Predictive value of quantitative plasma HIV RNA and CD4+ lymphocyte count in HIV-infected infants and children. JAMA. 1998;279:756-761 (Pubitemid 28115000)
7. Dunn D. HIV Pediatric Prognostic Markers Collaborative Study Group. Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis. Lancet. 2003;362:1605-1611 (Pubitemid 37443527)
8. World Health Organization (WHO). Report of the WHO Technical Reference Group, Paediatric HIV/ART Care Guideline Group Meeting. Geneva, Switzerland, 10-11 April 2008. http://www.who.int/hiv/topics/paediatric/en/ . Acesso: 08/01/09.
9. a semanas epidemioló gicas - janeiro a junho de 2007. http://www.aids.gov.br/data/documents/ storedDocuments/%7BB8EF5DAF-23AE-4891-AD36-1903553A3174%7D/%7B721527B6-FE7A- 40DF-91C4-098BE8C704E0%7D/Boletim2007-internet090108.pdf . Acesso: 07/01/09.
10. HIV Pediatric Prognostic Markers Collaborative Study Group. Use of total lymphocyte count for informing when to start antiretroviral therapy in HIV-infected children: a meta- analysis of longitudinal data. Lancet. 2005;366:1868-1874
11. World Health Organization (WHO). Antiretroviral Therapy for HIV infection in infants and children in resource-limited settings: towards universal access: recommendations for a public health approach. Geneva: WHO; 2006. http://www.who.int/hiv/pub/guidelines/paediatric020907.pdf . Acesso: 15/12/07.
12. Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Programa Nacional de DST e AIDS. Critérios de definição de casos de AIDS em adultos e crianças. Brasília: Ministério da Saúde; 2003. http://www.aids.gov. br/data/documents/storedDocuments/%7BB8EF5DAF-23AE-4891-AD36-1903553A3174%7D/ %7B2A9F7D1C-093E-4A04-8380-84ED432964A5%7D/criterios.pdf . Acesso: 15/12/07.
13. Centers for Disease Control and Prevention - CDC. 1994 revised classification system for Human Immunodeficiency Virus infection in children less than 13 years of age. MMWR Recomm Rep. 1994;43(RR-12):1-10
14. Sharland M, Blanche S, Castelli G, Ramos J, Gibb DM; PENTA Steering Committee. PENTA guidelines for use of antiretroviral therapy, 2004. HIV Med. 2004;5 Suppl 2:61-86. (Pubitemid 39077128)
15. Dean AG, Dean JA, Burton AH, Dicker RC. Epi Info: a general-purpose microcomputer program for public health information systems. Am J Prev Med. 1991; 7:178-182
16. Lepage P, Msellati P, Hitimana DG, Bazubagira A, Van Goethem C, Simonon A, et al. Growth of human immunodeficiency type 1-infected and uninfected children: a prospective cohort study in Kigali, Rwanda, 1988 to 1993. Pediatr Infect Dis J. 1996;15:479-485
17. World Health Organization (WHO). Joint United Nations Programme on HIV/AIDS (UNAIDS). Epidemiological fact sheet on HIV and Aids. Core data on epidemiology and response - Brazil. 2008 Update. http://www.who.int/globalatlas/ predefinedReports/EFS2008/full/EFS2008-BR.pdf . Acesso: 07/01/09.
18. Pinto JA. Marcadores prognósticos e diagnóstico precoceemuma coorte de crianças infectadas verticalmente pelo vírus da imunodeficiência humana tipo 1 (HIV-1) [tese]. Belo Horizonte, MG: Universidade Federal de Minas Gerais; 1999.
19. Pollack H, Glasberg H, Lee E, Nirenberg A, David R, Krasinski K, et al. Impaired early growth of infants perinatally infected with human immunodeficiency virus: correlation with viral load. J Pediatr. 1997;130:915-922
20. Miller TL, Easley KA, Zhang W, Orav EJ, Bier DM, Luder E, et al. Maternal and infant factors associated with failure to thrive in children with vertically transmitted human immunodeficiency virus-1 infection: the prospective, P2C2 human immunodeficiency virus multicenter study. Pediatrics. 2001;108:1287-1296
21. Chearskul S, Chotpitayasunondh T, Simonds RJ, Wanprapar N, Waranawat N, Punpanich W, et al. Survival, disease manifestations, and early predictors of disease progression among children with perinatal human immunodeficiency virus infection in Thailand. Pediatrics. 2002;110:e25.
22. Newell ML, Borja MC, Peckham C; European Collaborative Study. Height, weight, and growth in children born to mothers with HIV-1 infection in Europe. Pediatrics. 2003;111:e52-60.
23. Mofenson LM, Harris DR, Moye J, Bethel J, Korelitz J, Read JS, et al. Alternatives to HIV-1 RNA concentration and CD4+ to predict mortality in HIV-1-infected children in resource-poor settings. Lancet. 2003;362:1625-1627 (Pubitemid 37443531)
24. Cross Continents Collaboration for Kids (3Cs4kids) Analysis and Writing Committee. Markers for predicting mortality in untreated HIV-infected children in resource-limited settings: a meta-analysis. AIDS. 2008;22:97-105.
25. USPHS Guidelines for the use of antiretroviral agents in pediatric HIV infection. July 29, 2008. http://aidsinfo.nih.gov/contentfiles/ PediatricGuidelines.pdf . Acesso: 19/01/09.
26. PENTA guidelines for the use of antiretroviral therapy in HIV paediatric infection - 2008 draft revision. http://www.pentatrials.org/guide08.pdf . Acesso: 19/01/09.